November 1, 2024
Genetic Therapy Articles
October 25, 2024
Gene Therapy Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 1, 2024
Clinical Trial Download: The Potential of Optogenetic Therapy
By Yasha Modi, MD , Allen C. Ho, MD, Sulagna Bhattacharya, MBA
September 1, 2024
Upfront: How Far We've Come
By Peter K. Kaiser, MD
September 1, 2024
New Drug Therapies for Benign Retinal Tumors
By Mary E. Aronow, MD
July 25, 2024
Phase 2 LUNA Trial Data Presented at ASRS
July 19, 2024
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS
By Jennifer Ford, senior managing editor
July 17, 2024
Phase 2 PRISM Trial Data on 4D-150 Gene Therapy Presented at 2024 ASRS Meeting
By Jennifer Ford, senior managing editor
July 10, 2024
Optogenetic Therapy Shows Promise for Retinitis Pigmentosa
July 1, 2024
Ocugen Meets Dosing Milestone in Stargardt Disease Trial
By Rochelle Nataloni, contributing writer
July 1, 2024
CRISPR Trial Demonstrates Potential Advances for Inherited Blindness
By Rochelle Nataloni, contributing writer
July 1, 2024
Eye2Gene and Heidelberg Announce Collaborative Partnership
By Rochelle Nataloni, contributing writer
July 1, 2024
Sickle Cell Drug Shows Promise in Stabilizing Vision in Rare Genetic Disease
June 24, 2024
Macular Telangiectasia: New Hope on the Horizon
By Thomas A. Albini, MD, Michael A. Singer, MD
June 1, 2024
Regenxbio Publishes Data Supporting One-time Use of Gene Therapy for Wet AMD
By Rochelle Nataloni, contributing writer
June 1, 2024
The Landscape of Gene Therapy for Diabetic Retinopathy
By Priya Vakharia, MD, David A. Eichenbaum, MD
May 1, 2024
Subspecialty News May 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
By Jim Gallagher, senior managing editor
April 1, 2024
Gene Therapy for Wet Age-related Macular Degeneration
By Khiem Sy Nguyen, BS, Samaantar Joshi, BS, Karen M. Wai, MD, et al.
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
February 16, 2024
Retinal Physician eUpdate - February 16, 2024
By Steve Lenier
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
Clinical Trial Update October 2023
September 1, 2023
SUBSPECIALTY NEWS: Izervay FDA approval, ReST committee updates on Syfovre, and more.
By Rochelle Nataloni, contributing writer
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
SUBSPECIALTY NEWS: Mydriasis spray approved, laser and imaging devices cleared, new AI technology, and more.
By Rochelle Nataloni, contributing writer
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
By Rochelle Nataloni, contributing writer
June 1, 2023
Clinical Trial Update June 2023
May 1, 2023
SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
By Rochelle Nataloni, contributing writer
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
Key Questions at the Heart of Inherited Retinal Disease Gene Therapy Innovation
By Thomas A. Mendel, MD, PhD
March 1, 2023
A Basic Primer on Gene Therapy
By Thomas A. Ciulla, MD, MBA, Aumer Shughoury, MD
March 1, 2023
Gene Therapy for Dry AMD
By Ehsan Rahimy, MD, Austen N. Knapp, MD
March 1, 2023
Update on Optogenetics for Advanced Retinal Degenerations
By Joseph Martel, MD, Jose-Alain Sahel, MD
March 1, 2023
Current Challenges in Gene Therapy Trials
By Glenn C. Yiu, MD, PhD, Arshad M. Khanani, MD, MA, FASRS, Kathryn L. Pepple, MD, PhD
March 1, 2023
Clinical Trial Update March 2023
February 1, 2023
Clinical Trial Update: Special Edition 2023
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
Clinical Trial Update January/February 2023
November 1, 2022
SUBSPECIALTY NEWS: New data presented at AAO in dry AMD, ocular oncology, gene therapy, and more.
By Rochelle Nataloni, contributing writer
October 1, 2022
SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.
By Rochelle Nataloni, contributing writer
August 1, 2022
Suprachoroidal Drug Delivery Technology
By Thomas A. Ciulla, MD, MBA, Rafael V. Andino, MSBE, MBA, Shelley Hancock, MBA
August 1, 2022
Suprachoroidal Delivery as a Novel Avenue for Retinal Gene Therapy
By Arshad M. Khanani, MD, MA, FASRS, Hannah Khan, MPH, Tyler M. Ewing, MS
March 1, 2022
SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
By Rochelle Nataloni, contributing writer
January 1, 2022
SUBSPECIALTY NEWS: Real-world Iluvien data, advances to program for choroidal melanoma treatment, results for at-home OCT, and more.
By Rochelle Nataloni, contributing writer
Advertisement
Recommendations
Advertisement